IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.543
NA - Nord America 1.557
EU - Europa 683
SA - Sud America 281
AF - Africa 43
OC - Oceania 25
Totale 11.132
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 6.815
US - Stati Uniti d'America 1.482
CN - Cina 760
HK - Hong Kong 675
BR - Brasile 197
GB - Regno Unito 189
IT - Italia 162
VN - Vietnam 136
DE - Germania 111
IN - India 49
CA - Canada 46
FI - Finlandia 37
NL - Olanda 34
AR - Argentina 31
CZ - Repubblica Ceca 28
AU - Australia 24
MX - Messico 23
PL - Polonia 23
TR - Turchia 22
FR - Francia 21
ZA - Sudafrica 20
EC - Ecuador 18
UA - Ucraina 18
ID - Indonesia 17
JP - Giappone 17
ES - Italia 16
BD - Bangladesh 12
PY - Paraguay 11
CL - Cile 9
SE - Svezia 8
CH - Svizzera 5
RU - Federazione Russa 5
CO - Colombia 4
ET - Etiopia 4
MA - Marocco 4
SA - Arabia Saudita 4
UY - Uruguay 4
AT - Austria 3
BE - Belgio 3
BY - Bielorussia 3
EG - Egitto 3
IR - Iran 3
LU - Lussemburgo 3
PE - Perù 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DZ - Algeria 2
IL - Israele 2
IQ - Iraq 2
IS - Islanda 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
MY - Malesia 2
PA - Panama 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TL - Timor Orientale 2
VE - Venezuela 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GH - Ghana 1
GN - Guinea 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
IE - Irlanda 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
ML - Mali 1
MU - Mauritius 1
NP - Nepal 1
PK - Pakistan 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
Totale 11.132
Salva come PNG Salva come JPEG
Città #
Hong Kong 666
Singapore 509
Hefei 391
Ashburn 319
Boardman 216
Dallas 178
London 155
Shanghai 134
Beijing 122
Rome 70
Munich 62
Los Angeles 61
Council Bluffs 57
Ho Chi Minh City 51
San Francisco 46
Seattle 31
Brno 28
São Paulo 28
New York 26
Pune 26
Santa Clara 26
Turku 22
West Jordan 22
Warsaw 21
Hanoi 20
Amsterdam 19
Guangzhou 19
Toronto 19
Washington 17
Mexico City 16
Tokyo 16
Helsinki 15
Montreal 15
Boston 14
Rio de Janeiro 13
Canberra 12
Sona 11
Johannesburg 10
Chennai 9
Da Nang 9
Brooklyn 8
Stockholm 8
Atlanta 7
Chicago 7
Guayaquil 7
Haiphong 7
Melbourne 7
Paris 7
Shenzhen 7
Charlotte 6
Manchester 6
Redmond 6
Milan 5
Secaucus 5
Sydney 5
Thái Bình 5
Zhengzhou 5
Ankara 4
Brasília 4
Buenos Aires 4
Central 4
Curitiba 4
Frankfurt am Main 4
Hải Dương 4
Kyiv 4
Naples 4
Phoenix 4
Quito 4
The Dalles 4
Addis Ababa 3
Bari 3
Bologna 3
Boydton 3
Brownsville 3
Buffalo 3
Bắc Giang 3
Camden 3
Haikou 3
Jackson 3
Lima 3
Montevideo 3
Oklahoma City 3
Poplar 3
Providence 3
Rabat 3
Riyadh 3
Shijiazhuang 3
Suzhou 3
Thái Nguyên 3
Tianjin 3
Valsamoggia 3
Vienna 3
Anderlecht 2
Andover 2
Asunción 2
Bangkok 2
Belém 2
Berlin 2
Biên Hòa 2
Bogotá 2
Totale 3.742
Salva come PNG Salva come JPEG
Nome #
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 221
Advances in management of periprosthetic joint infections: an historical prospective study 208
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 205
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 203
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 201
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 198
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 198
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 196
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 194
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 190
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 189
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 189
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 188
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 187
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 187
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 186
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 186
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 185
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 182
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 179
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 178
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 177
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 177
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 176
Assessment of liver function by the exhaled breath-print during chronic liver disease 173
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 134
GH-resistance in different stages of chronic liver disease 108
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 107
Diabetes in chronic liver disease: from old concepts to new evidence 103
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 101
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 98
[A 73-year-old woman with vomiting and metabolic alkalosis] 98
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 97
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 93
A challenging alfa-fetoprotein in a cirrhotic patient 91
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 90
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 89
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 89
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 87
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 87
[A 61-year-old woman with abdominal pain and urination disorders] 85
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 85
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 85
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 81
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 80
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 80
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 79
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 79
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 78
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 77
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 76
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 72
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 70
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 68
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 65
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 65
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 64
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 61
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 59
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 58
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 49
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 44
Pain and Frailty in Hospitalized Older Adults 42
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 42
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 39
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 38
TNF-alpha and growth hormone resistance in patients with chronic liver disease 37
Reelin expression in human liver of patients with chronic hepatitis C infection 37
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 37
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease 36
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 36
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 36
Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma 35
Identification of Fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure 35
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 35
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 34
Reply to the Letter: “Low levels of transaminase and mortality risk in older people with special reference to sarcopenia” 34
The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection 33
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 33
Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients 33
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 32
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. 32
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development 32
Hepatic matrix metalloproteinase-10 exerts a hepatoprotective role after acute liver inury 32
Identification of matrix metalloprotease 10 (mmp10) as a key new mediator of the regenerative response of the liver 32
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 32
What changed in the Italian internal medicine and geriatric wards during the lockdown 32
The pharmacological treatment of chronic comorbidities in COPD: mind the gap! 31
Multimorbidity and polypharmacy in the elderly: lessons from REPOSI 31
Interplay between SIRT-3, metabolism and its tumor suppressor role in hepatocellular carcinoma 31
Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis 31
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures 30
The hepatic expression of GH/IGF1 axis components is impaired with fibrosis progression in patients with HCV-related chronic hepatitis 30
MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION 30
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen 30
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice 30
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease 29
Rare ATG7 genetic variants predispose patients to severe fatty liver disease 29
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b 29
Renal impairment and anemia during triple therapy 29
Totale 9.051
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022336 0 2 8 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20261.743 620 332 457 334 0 0 0 0 0 0 0 0
Totale 11.208